About our Biomedical Research Centre

The NIHR Great Ormond Street Hospital (GOSH) Biomedical Research Centre in partnership with the University College London (UCL) Great Ormond Street Institute of Child Health is the leading children’s medical research centre in Europe and the only Biomedical Research Centre dedicated to children.

GOSH Biomedical Research Centre’s vision is to transform the health of children, and the adults they will become, by combining cutting edge research methods with world-leading clinical trial expertise, to accelerate discovery of new treatments for children with rare and complex conditions worldwide. Involving these patients, their parents/carers and the public in the research process is essential to achieving our mission.

GOSH and the UCL Great Ormond Street Institute of Child Health were first awarded Biomedical Research Centre status by the National Institute for Health Research (NIHR) in 2007 and, in 2016, we secured £37 million for our third term, running to November 2022.

For our third term, running to November 2022, we will focus on four major Research Themes:

Gene, stem and cellular therapies aims to refine, advance and expand our state-of-the-art infrastructure to enable the delivery of new gene and cell therapies into the NHS.

Genomics and systems medicine aims to further develop personalised medicine for the NHS.

Novel therapies and their translation into childhood diseases aims to initiate and conduct high quality clinical trials in our rare disease population.

Advanced treatments for structural malformation and tissue damage aims pioneer advanced treatments, such as regenerative medicine, and develop new devices to provide therapeutic options for children with congenital malformations and tissue damage.

All activity at the NIHR GOSH BRC is underpinned by four Cross-cutting Themes:

GOSH rare disease cohorts aims to carefully define cohorts of patients to maximise health informatics data and sample collection, and better inform novel diagnostics and therapeutic interventions.

BRC experimental medicine academy invests in training and education for both non-clinical and clinical professionals including medics and allied health professionals.

Clinical Research Facility (CRF) funding from the BRC supports high intensity, early-phase clinical trials which require inpatient or intensive care accommodation. Support will be in the form of a team consisting of an Advanced Nurse Practitioner and research nurses.

Translation research and enterprise accelerator aims to accelerate partnerships through initiatives such as support in intellectual property (IP) protection, trial design, ‘match making’ with industrial partners and facilitating licencing agreements.